Holdings
Lynx1 Capital Management LP
As of Jun 30, 2026, Lynx1 Capital Management LP reported 24 positions worth US$508M. Largest: Cullinan Therapeutics, Inc., Stoke Therapeutics, Inc. and Agios Pharmaceuticals, Inc. What it bought and sold, with each filing.
| Company | Shares | Value as reported | Change | As of |
|---|---|---|---|---|
| Cullinan Therapeutics, Inc. | 8.96M | US$163M | no change | Jun 30, 2026 |
| Stoke Therapeutics, Inc. | 4.04M | US$132M | −725K | Jun 30, 2026 |
| Agios Pharmaceuticals, Inc. | 3.41M | US$127M | +797K | Jun 30, 2026 |
| C4 Therapeutics, Inc. | 7.33M | US$34.2M | +328K | Jun 30, 2026 |
| Korro Bio, Inc. | 1.54M | US$20.3M | no change | Jun 30, 2026 |
| Tscan Therapeutics, Inc. | 8.02M | US$7.86M | no change | Jun 30, 2026 |
| Precision Biosciences, Inc. | 950K | US$7.47M | −34,647 | Jun 30, 2026 |
| Neuphoria Therapeutics Inc. | 875K | US$3.83M | no change | Jun 30, 2026 |
| Passage Bio, Inc. | 674K | US$3.29M | +50,055 | Jun 30, 2026 |
| Cg Oncology, Inc. | 31,391 | US$2.23M | −200 | Jun 30, 2026 |